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Background: We examined the presence and function of tachykinins and the tachykinin-degrading enzymes
neprilysin (NEP) and neprilysin-2 (NEP2) in human spermatozoa.
Methods: Freshly ejaculated semen was collected from forty-eight normozoospermic human donors. We analyzed
the expression of substance P, neurokinin A, neurokinin B, hemokinin-1, NEP and NEP2 in sperm cells by reverse-
transcriptase polymerase chain reaction (RT-PCR), western blot and immunocytochemistry assays and evaluated the
effects of the neprilysin and neprilysin-2 inhibitor phosphoramidon on sperm motility in the absence and presence
of tachykinin receptor-selective antagonists. Sperm motility was measured using WHO procedures or computer-
assisted sperm analysis (CASA).
Results: The mRNAs of the genes that encode substance P/neurokinin A (TAC1), neurokinin B (TAC3), hemokinin-1
(TAC4), neprilysin (MME) and neprilysin-2 (MMEL1) were expressed in human sperm. Immunocytochemistry studies
revealed that tachykinin and neprilysin proteins were present in spermatozoa and show specific and differential
distributions. Phosphoramidon increased sperm progressive motility and its effects were reduced in the presence
of the tachykinin receptor antagonists SR140333 (NK1 receptor-selective) and SR48968 (NK2 receptor-selective) but
unmodified in the presence of SR142801 (NK3 receptor-selective).
Conclusion: These data show that tachykinins are present in human spermatozoa and participate in the regulation
of sperm motility. Tachykinin activity is regulated, at least in part, by neprilysins.
Background
There is now convincing evidence that tachykinins are
involved in the regulation of reproductive function [1-8].
Recent data have demonstrated that tachykinin recep-
tors are present in human sperm and are functionally
active suggesting a role for the tachykinin system in the
regulation of sperm function [9].
Mammalian tachykinins comprise a family of regula-
tory peptides including substance P (SP), neurokinin A
(NKA), neurokinin B (NKB) and hemokinin-1 (HK-1)
[10-15]. In humans, tachykinins are the products of
three different genes. The TAC1 gene gives rise to four
different mRNA splicing isoforms (a, b, g and δ)t h a t
encode SP (a, b, g and δ)a n dN K A( b and g). The
TAC3 gene encodes NKB. The TAC4 gene can also
generate four distinct mRNAs, named a, b, g and δ,a l l
of which encode HK-1 [1,4,11,12]. Tachykinins effects
are mediated by three receptors named NK1,N K 2 and
NK3, which, in humans, are encoded by the TACR1,
TACR2 and TACR3 genes, respectively [15-19]. The
NK1 receptor is activated preferentially by SP and HK-1,
the NK2 receptor by NKA, and the NK3 receptor by
NKB [15-19].
The neutral endopeptidase EC 3.4.24.11, also named
enkephalinase or neprilysin (NEP) is the major peptidase
that degrades tachykinins in most human tissues
[8,20-23]. NEP also degrades other bioactive peptides
such as enkephalins, angiotensins, endothelin-1, chole-
cystokinins and bradykinin [24-28]. The enzyme is
e x p r e s s e di nh u m a ns p e r m[ 9 , 2 5 - 2 7 ]a n di t si n h i b i t i o n
by thiorphan causes a change in sperm motility that is
partially mediated by opioids [27]. In addition to classi-
cal NEP, a homologous enzyme was recently described
and named neprilysin-2 (NEP2) [29]. Human NEP2 has
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tachykinins and angiotensin I with efficiency similar to
NEP [28]. There are also important differences between
enzyme sensitivity to the classical inhibitors, thiorphan
and phosphoramidon. Thus thiorphan behaves as a
selective NEP inhibitor while phosphoramidon inhibits
both enzymes with almost equal potency [24,28]. NEP2
is expressed predominantly in the testis [29-31] and stu-
dies in mice deficient in NEP2 have shown that this
enzyme is involved in sperm function and oocyte fertili-
zation [31]. However, the role of NEP2 in human repro-
duction has not jet been established.
In the present study, we investigated the expression
and cellular localization of tachykinins and the tachyki-
nin-degrading enzymes NEP and NEP2 in human sper-
matozoa, analyzed the effects of the NEP and NEP2
inhibitor phosphoramidon on sperm motility, and deter-
mined whether endogenous tachykinins are involved in
the responses observed after neprilysin inhibition.
Methods
Chemicals
SR140333, SR48968 and SR142801 were a generous gift
from Sanofi Recherche (Montpellier, France). Phosphor-
amidon was from Sigma (St. Louis, MO, USA). Drugs
were dissolved in distilled water (phosphoramidon) or
absolute ethanol (tachykinin receptor antagonists) and
diluted into sperm washing medium to appropriate
concentrations.
Semen samples and sperm preparation
Freshly ejaculated semen was collected from forty-eight
healthy donors (18-35 years old) after 3-4 days of sexual
abstinence. The study was approved by the Ethics Com-
mittee of Consejo Superior de Investigaciones Científicas
(CSIC) and all donors gave written informed consent. The
samples were allowed to liquefy at 37°C for 30 min and
examined for concentration and motility following World
Health Organization (WHO) guidelines [32]. Liquefied
semen samples were washed with modified human tubal
fluid (mHTF, Irvine Scientific, Santa Ana, CA, USA) sup-
plemented with 0.5% bovine serum albumin (BSA) and
processed as previously described [9]. Briefly, sperm sus-
pensions were centrifuged through Spermgrad-125 (Vitro-
life, Kungsbacka, Sweden), washed in mHTF, allowed to
swim-up for 1 hour at 37°C and the supernatant carefully
aspirated. Semen motility and concentration were visually
re-examined and the concentration adjusted to 50 million
per ml for subsequent experiments.
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was extracted from sperm pools from 8 dif-
ferent donors using TriReagent (Sigma) and cDNA was
synthesized using the Quantitect Reverse Transcription
kit (Qiagen, Venlo, The Netherlands). Specific oligonu-
cleotide primer pairs used to amplify TAC1, TAC3,
TAC4,t h ea, b, g and δ isoforms of TAC1 and TAC4,
the genes that encode NEP (MME), NEP2 (MMEL1), b-
actin (ACTB)a c r o s i n( ACR)a n dCD4 are shown in
Table 1 and were synthesized and purified by Sigma
Genosys (Cambridge, UK). ACTB served as an internal
control while ACR and CD4 were used to verify the pre-
sence of sperm cDNA and to exclude the presence of
leukocyte contamination, respectively [33-35]. Gene
expression was also analyzed in human testis and in a
pool of cDNAs from twenty different human tissues
(human total RNA master panel, BD Biosciences Clon-
tech, Palo Alto, CA) used as a positive control of
amplification.
Table 1 Sequences of forward (F) and reverse (R) primers of indicated target and reference genes
Gene Forward Primer Reverse Primer Amplicon size (bp)
TAC1 ACTGTCCGTCGCAAAATCC ACTGCTGAGGCTTGGGTCTC 212
a/δTAC1 GGAGCCCTTTGAGCATCTTC CTTTCATAAGCCATTTTGTGAGAGA 168/123
b/gTAC1 GGAGCCCTTTGAGCATCTTC TTCATAAGCCACAGAATTTAAAGCTC 220/175
TAC3 CCAGTGTGTGAGGGGAGCA TCCAGAGATGAGTGGCTTTTGA 266
TAC4 GG TCTCTTCTCTGTGTCTCCTGTCCTC CATTTATTGAGTGCCTACTGTGTGCT 246
aTAC4v1 TGTGGCCTTGGAGGAAGG ACTGCTGCTTGACACTGAGA 415
aTAC4v2 GCCAAGGAGAAAAAAAGCAT ACTGCTGCTTGACACTGAGA 292
b-TAC4 GGAAGCGAGTGGGAGCAT ACTGCTGCTTGACACTGAGA 290
δ-TAC4 AGTGGGAGGCAGAGAGGAT ACTGCTGCTTGACACTGAGA 223
g-TAC4 AAGGAGAAAAAAAGGCAGAGAG ACTGCTGCTTGACACTGAGA 229
MME AGCCTCTCGGTCCTTGTCCT GGAGCTGGTCTCGGGAATG 219
MMEL1 TGGACATCTTGGAGGTGGTG GGAGTTCTGGTCGTCGTTCC 164
ACTB TCCCTGGAGAAGAGCTACGA ATCTGCTGGAAGGTGGACAG 362
ACR CCCTCCCATTTCGTGTGG CACAAGTCCAGGTCGATGAGA 180
CD4 AGAAAGACGCAAGCCCAGAG GCACCAGAAGCAAGTGCCTAA 127
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3 μl of cDNA reaction mixture, 2.5 mM MgCl2,0 . 2μM
primers, 200 μMd N T P ’s and 1.5 U of DNA polymerase
(Immolase, Bioline, London, UK). Cycling parameters
were: 15 s at 94°C; 20 s at 60°C and 20 s at 72°C for 35
cycles. In some experiments, a 1/50 dilution of amplified
cDNA was reamplified in the same PCR conditions and
with the same primers. The PCR products were sepa-
rated by gel electrophoresis on 2.5% agarose. The ampli-
con sizes were verified by comparison with a DNA size
ladder and the identity of the products was established
by sequence analysis.
Indirect immunofluorescence
Sperm cells were washed, resuspended in phosphate-
buffered saline (PBS) and smeared onto poly-L-lysine-
coated slides. Spermatozoa were fixed in cold methanol
(-20°C, 20 min) and incubated with 2% casein in PBS
for 120 min to block non-specific sites. Test slides were
incubated with a primary polyclonal antibody designed
to recognize SP (sc-9758, dilution 1:200), NKB (sc-
14109, dilution 1:200), HK-1 (sc-47439, dilution 1:500),
NEP (sc-9149, dilution 1:200) from Santa Cruz Biotech-
nology (Santa Cruz, CA); NKA (T-4446, dilution 1:400),
NKB (T-4450, dilution 1:400) from Peninsula Labora-
tories Inc. (San Carlos, CA) and NEP2 (HPA 007876,
dilution 1:400, recommended by the supplier for immu-
nocytochemistry and sc-104450, dilution 1:100, recom-
m e n d e df o rw e s t e r nb l o t )f r o mS i g m aa n dS a n t aC r u z ,
respectively. Primary antibodies were incubated over-
night at 4°C diluted in PBS. The specificity of antibodies
was assessed by bibliographic references or by pre-
absorption with the corresponding immunogenic pep-
tide. Negative control slides were not exposed to the
primary antibody and were incubated with a) rabbit or
goat IgG or b) PBS and processed in the same condi-
tions as the test slides. Samples were incubated for 60
min with appropriate FITC-conjugated secondary anti-
bodies (Santa Cruz), mounted using Prolong Gold anti-
fade reagent (Invitrogen, Molecular Probes, Eugene, OR)
a n de x a m i n e dw i t ha nO l y m p u sB X - 5 1f l u o r e s c e n c e
microscopy (Tokyo, Japan).
Western blot analysis
Western blotting was used to assess the specificity of
NEP and NEP2 antibodies and performed essentially as
described previously [9]. Sperm cells were obtained as
indicated above. Seminal plasma was obtained by centri-
fugation of semen samples at 12000 × g for 10 min.
Total proteins from semen or seminal plasma samples
were extracted by sonication in urea extraction buffer
(1% w/v SDS, 9 M Urea, 1 mM EDTA, 0.7 M mercapto-
ethanol, in 25 mM Tris-HCl, pH 6.8), boiled for 2 min
and processed by the PAGEprep Advance kit (Pierce,
Rockford, IL). Proteins were separated by electrophor-
esis on 10% SDS-PAGE gels, transferred to polyvinyldi-
fluoride (PVDF) membranes and processed with the
Amersham advance ECL kit (Amersham, Buckingham-
shire, UK). Primary antibody dilution was 1:10000 and
for the secondary antibody was 1:100000.
Human sperm motility studies
Motility analysis was performed manually or using a
computer-assisted sperm analysis (CASA) system
(Sperm Class Analyzer, Microptic, Barcelona, Spain)
essentially as described previously [9,33]. Aliquots of
semen samples (5 μL) were placed into a Makler Count-
ing Chamber (Sefi Medical Instruments Ltd., Haifa,
Israel) and at least 200 sperm cells were evaluated at
each incubation time by phase contrast microscopy.
Sperm movement was graded following WHO guide-
lines [32] and defined as: a: rapid progressive motility; b:
slow progressive motility; c: non-progressive motility
and d: immotility. Progressive motility (a+b), non-pro-
gressive motility (c) and immotility (d)w e r em e a s u r e d
as percentage of the total (a+b+c+d)t h a tw a sc o n s i d -
ered as 100%.
Individual sperm samples were divided in several ali-
quots and each aliquot was untreated (time-matched
paired controls) or treated with a single concentration
of phosphoramidon (1 nM-1 μM) or the corresponding
solvent. Sperm motility was measured 5 min before
agent addition (initial value) and after 1, 15, 60, 120 and
240 min contact time periods. The effect of phosphora-
midon (1 μM) or its solvent were also investigated in
aliquots pretreated for 45 min with the tachykinin NK1
receptor-selective antagonist SR140333 (10 nM) [36],
the NK2 receptor-selective antagonist SR48968 (10 nM)
[37], the NK3 receptor-selective antagonist SR142801
(10 nM) [38], a cocktail of the three antagonists (10 nM
each) or the corresponding solvent. A maximum of two
drug concentrations, or the corresponding solvent
volume, were tested on each aliquot. Values of sperm
progressive motility, non-progressive motility and
immotility were expressed as the positive or negative
percentage increment in motility produced by the drug
relative to the value observed at the same time in sol-
vent-treated or time-matched paired controls (Δ sperm
motility).
The effects of phosphoramidon on sperm kinetic para-
meters were analyzed by CASA, with settings according
to instructions by the manufacturer. The measured
kinetic parameters were curvilinear velocity (VCL);
straight-line velocity (VSL), average path velocity (VAP);
percent linearity (LIN = VSL/VCL × 100) and percent
straightness (STR = VSL/VAP × 100).
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Values (means ± SEM) were obtained by pooling indivi-
dual data and n indicates the number of experiments in
samples from n different donors. Statistical analyses
were made using Mann-Whitney’s U (for comparison of
mean ranks between two groups) or Kruskal-Wallis (to
compare more than two groups) nonparametric tests.
These procedures were undertaken using GRAPHPAD
PRISM (version 5.0). P <0 . 0 5v a l u e sw e r ec o n s i d e r e d
significant.
Results
mRNA expression of tachykinins and neprilysins in human
sperm
The genes that encode SP/NKA (TAC1), NKB (TAC3),
hHK-1(TAC4), NEP (MME) and NEP2 (MMEL1)w e r e
detected in cDNAs from human sperm, testis and the
pool of 20 human tissues used as positive control (Fig. 1).
In sperm, the mRNAs of TAC4 and MME were only
visualized after cDNA reamplification. Using specific pri-
mers and cDNA reamplification, we observed that,
among the TAC1 isoforms, only the g and δ transcripts
were detectable in human spermatozoa (Fig. 1). TAC1-b,
TAC1-g and TAC1-δ were expressed in human testis, the
last one being only observed after cDNA reamplification.
Splice variants of the TAC4 gene were present in the
positive control but were undetected in testis and sperm
cDNAs (data not shown). We also verified the presence
of ACTB and ACR and the absence of CD4 mRNA in all
sperm samples (Fig. 1, not shown for ACTB).
Three negative controls were included in all assays (no
reverse transcriptase, no RNA in the reverse transcrip-
tase reaction and no template) and no PCR product was
detected in any of these controls.
Immunodetection of tachykinins and neprilysins in
human sperm
Immunocytochemistry demonstrated positive immunos-
taining for tachykinins, NEP and NEP2 in sperm cells
(Figs. 2, 3 and 4). Intense SP labeling was observed over
the acrosomal region and around the connecting piece
in approximately 80% of the cells. In the other cells, SP
Figure 1 Gene expression of tachykinin precursors, neprilysin (MME) and neprilysin-2 (MMEL1) in human sperm (SPZ) and testis (TES).
In human sperm, the specific bands corresponding to TAC1 g and δ isoforms, TAC4 and MME were only detected after cDNA reamplification.
Acrosin (ACR) was present in sperm and testis cDNA while CD4 was only detected in testis. (+), positive control showing the expression of all
genes in a pool of cDNAs from twenty different human tissues. (-), negative control with no RNA in the reverse transcriptase reaction; M,
molecular size standards. The figure is representative of results in 6 pools of sperm samples from 8 different donors.
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ing piece and the flagellum principal piece (Fig. 2A).
NKA was mainly found around the neck with a less
intense immunostaining of the sperm head and the fla-
gellum principal piece. NKB immunofluorescence was
restricted to the equatorial segment and the post-equa-
torial region of the head (Fig. 2A). We found identical
NKB immunolocalization with two different antibodies.
HK-1 was present in the postacrosomal region and
along the tail and intense labeling was detected in the
flagellum midpiece being the only tachykinin that was
present in this sperm area (Fig. 2B). Preincubation of
the primary antiserum with SP or HK-1 immunogenic
peptide (5 μg/ml) caused a disappearance of the fluores-
cent signal (Fig. 2B, not shown for SP). NEP immunos-
taining was localized in the equatorial segment
in approximately 80% of cells, detected around the
neck in a small, different population of sperm cells
(approximately 3%) or undetectable (Fig. 3A). NEP2 was
localized around the equatorial segment and the post-
acrosomal region of spermatozoa with the HPA 007876
antibody (Fig. 3A). Unspecific binding was not observed
in the presence of preimmune rabbit or goat serum and
there was no immunofluorescence in the absence of the
corresponding primary antibody.
Western blot confirmed the specificity of NEP and
NEP2 antibodies and showed the presence of both
enzymes in seminal plasma and of NEP2 in spermato-
zoa. The NEP antibody labeled a band of approximately
100 kDa (Fig. 3B). In agreement with previous data [27]
the NEP signal was not observed in sperm. The NEP2
antibody HPA 007876, used in immunocytochemistry
studies, recognized a band of approximately 90 kDa, the
size expected for the major membrane-bound human
NEP2 isoform [32]. As a positive control, we used a sec-
ond human NEP2 antibody, sc-104450, recommended
by the supplier for western blot. This second NEP2 anti-
body labeled the 90 kDa band in both spermatozoa and
seminal plasma (Fig. 3B). In seminal plasma it recog-
nized a second band, of approximately 130 kDa, which
may correspond to an already described, additional
membrane-associated isoform or to the soluble form of
human NEP2 [32]. A third unknown band of approxi-
mately 50 kDa was detected with the sc-104450 anti-
body in seminal plasma and sperm cells. The
Figure 2 Immunofluorescent localization of tachykinins in
human sperm. (A) Immunofluorescence and corresponding
differential interference contrast images of sperm cells stained with
primary antibodies against substance P (SP), neurokinin A (NKA) and
neurokinin B (NKB) showing specific localizations for each peptide.
(B) Immunofluorescence and corresponding phase contrast images
of sperm cells stained with a primary antibody against hemokinin-1
(HK-1) in the absence (a) and in the presence (b) of immunogenic
peptide. For each tachykinin, experiments were performed at least
six times with similar results. Scale bar, 10 μM.
Figure 3 Localization of neprilysins in human sperm.( A )
Immunofluorescence and corresponding differential interference
contrast images of sperm cells stained with primary antibodies
against neprilysin (NEP) and neprilysin-2 (NEP2). Experiments were
performed at least six times with similar results. Scale bar, 10 μM. (B)
Western Blot analysis of NEP and NEP2 in human spermatozoa (SPZ)
and seminal plasma (SP) homogenates. For NEP2, SP and SPZ1
represent results obtained with the NEP2 antibody sc-104450 and
SPZ2 represents results obtained with the NEP2 antibody HPA
007876 (see text for further details). Results are representative of at
least five separate protein preparations, each from eight different
donors.
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observed when primary antibodies were omitted (data
not shown).
Effects of phosphoramidon on human sperm motility
The NEP and NEP2 inhibitor phosphoramidon caused
time- and concentration-dependent increases in the pro-
portion of progressively motile sperm (Fig. 4). The mag-
nitude of the effect of phosphoramidon was inversely
related to the initial proportion of progressive motile
sperm in the sample. Thus, in samples with initial values
of sperm progressive motility of 45-60%, the percentage
of grade a+b sperm was 64.8 ± 3.8 in samples treated
with 1 μM phosphoramidon for 60 min and 51.0 ± 3.2
in time-matched paired aliquots (P < 0.05). Sperm pro-
gressive motility was not affected by the phosphorami-
don solvent (50.0 ± 3.3, P > 0.05 vs. time-matched
controls). The results were similar when sperm motility
was measured manually (Fig. 4A, B) or by CASA (Fig.
4C). The use of CASA revealed that phosphoramidon
increased particularly the percentage of grade a sperma-
tozoa (Fig. 4C). With regard to sperm kinetimatic para-
meters, CASA analysis showed that phosphoramidon
increased straightness (by 6.13 ± 1.74%) and linearity
(by 7.56 ± 0.98%) (P <0 . 0 5vs. solvent-treated aliquots)
leading to a motility pattern characteristic of non-hyper-
activated sperm.
We then analyzed whether tachykinin receptors could
mediate the actions of phosphoramidon on sperm moti-
lity. The effect of phosphoramidon (1 μM, 60 min incu-
bation) was reduced by preincubation of the sperm
sample for 45 min with the NK1 receptor-selective
antagonist SR140333 (10 nM) or the NK2 receptor-
selective antagonist SR48968 (10 nM) but was not
affected by the NK3 receptor-selective antagonist
SR142801 (10 nM) (Fig. 5). The phosphoramidon-
induced effect was reduced, but not abolished, in the
presence of a combination of the three tachykinin recep-
tor antagonists (each at a concentration of 10 nM, Fig
5). The antagonist solvent had no effect on phosphora-
midon responses (Fig 5).
Discussion
In the present study, the major findings are: a) the
tachykinin peptides, SP, NKA, NKB and HK-1 are pre-
sent in human sperm; b) the two most important
enzymes involved in tachykinin metabolism, NEP and
NEP2 are expressed in human spermatozoa and c) the
endogenous tachykinins modulate the motility of these
cells.
The mRNAs of TAC1, TAC3 and TAC4, coding for
the human tachykinin peptides, were expressed in
sperm (9, this study). Among the TAC1 isoforms, only
TAC1-g and the rare TAC1-δ were present in
spermatozoa. Conversely, the a and b isoforms were
absent, in spite of the fact that TAC1-b is one of the
most abundant TAC1 isoforms in many human cells
and tissues including the testis [2,6,14]. With respect to
TAC4, none of its splicing variants was detected.
Increasing evidence suggests that the specific fraction of
mRNAs that stays in mature spermatozoa plays some
role in subsequent fertilization steps or is required for
adequate embryo formation [39-42]. In this context,
recent reports have established the existence of impor-
tant differences between the sperm transcriptome of fer-
tile and infertile men [42] providing clinical support for
the relevance of sperm mRNA in male fertility.
The mRNAs of all tachykinins were present in human
testis and sperm. Because spermatozoa are considered
transcriptionally silent cells, the presence of these
mRNA unequivocally proves that the genes encoding
these proteins are transcribed in germ cells at any step
during spermatogenesis. In addition, immunocytochem-
istry studies revealed that all tachykinin peptides were
present in mature spermatozoa. Major labeling was
observed over the acrosomal region for SP, around the
connecting piece for NKA, in the equatorial/post-acro-
somal region for NKB and around the midpiece for
HK-1. This regional pattern of distribution argues for a
specific role for each tachykinin in the regulation of
s p e r mf u n c t i o n .T h ep r e s e n c eo fN K Bi nt h ee q u a t o r i a l
segment suggests that this tachykinin could be involved
in the fertilization process because this segment appears
important in the fusion of gametes [43]. It has recently
been shown that the NKB/NK3 ligand-receptor pair
plays a central role in the regulation of reproductive
functions [4-9]. In this context, it is interesting to note
that NKB immunostaining was in a similar location
than that previously found for the tachykinin NK3
receptor [9].
The local bioactivity of peptide signaling molecules is
tightly controlled by their enzymatic degradation. Our
data show that NEP and NEP2, the most important
enzymes involved in tachykinin metabolism, are
expressed in human sperm at both mRNA and protein
levels. In reference to NEP, the data confirm previous
results showing the expression of this enzyme in sperm
[25-27]. With respect to NEP2, we report for the first
time the presence of this enzyme in human spermato-
zoa. The observation that NEP2 was placed around the
equatorial segment of human spermatozoa support a
role for this enzyme in sperm fertilizing ability. These
data are in line with previous findings showing that
sperm from NEP2 knockout mice show apparently nor-
mal characteristics but lower oocyte fertilization and
reduced embryo development [31].
NEP and NEP2 were abundant in seminal plasma sug-
gesting that the activity of their substrates must be
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Page 6 of 10Figure 4 Time- and concentration-dependent effects of phosphoramidon on human sperm motility. Motility analysis was performed
manually (A, B) or using a computer-assisted sperm analysis (CASA) system (C). (A) Effects of phosphoramidon (1 nM-1 μM) or its solvent on
progressive motility (grade a+b sperm) at different times of incubation (B) Effects of phosphoramidon (1 μM) on progressive motility (grade a+b
sperm), non-progressive motility (grade c sperm) and immotility (grade d sperm) at different times of incubation. (C) Effects of phosphoramidon
(1 μM) on grade a and grade b sperm at different times of incubation. Bars are means with SEM of 6-13 different experiments and represent
percentage changes in motility in samples treated with phosphoramidon relative to the value observed at the same time in untreated (A) or
solvent-treated (B, C) paired controls. *P < 0.05, significant difference vs. control responses.
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male reproductive tract and/or during ejaculation. In
mature spermatozoa, inhibition of both enzymes by
phosphoramidon caused an increase in sperm progres-
sive motility. Sperm motility is an important feature and
the most reliable actual predictor of male factor inferti-
lity [44,45]. Our data show that phosphoramidon
induced a rise in straightness and linearity leading to
motility trajectories that are characteristics of non
hyperactivated spermatozoa and this is important
because only spermatozoa with good progressive moti-
l i t ya r ea b l et os w i mt h r o u g ht h ef e m a l er e p r o d u c t i v e
tract and reach the oviduct.
The responses elicited by phosphoramidon were
reduced in the presence of SR140333, a selective antago-
nist of the tachykinin NK1 receptor [36], and in the pre-
sence of SR48968, a selective antagonist of the
tachykinin NK2 receptor [37]. This demonstrates that
the effects observed after neprilysin inhibition are
mediated, at least in part, by tachykinins acting at the
NK1 and the NK2 receptor. Conversely, the effects of
phosphoramidon were unaffected in the presence of
SR142801, a selective antagonist of the tachykinin NK3
receptor [38], consistent with our previous data which
showed that the NK3 receptor plays a minor role in
mediating motility changes induced by exogenously
applied tachykinins in human sperm [9].
The effects of phosphoramidon were reduced, but not
abolished, in the presence of a combination of
SR140333, SR48968 and SR142801. NEP and NEP2 par-
ticipate in degradation of other peptides, such as angio-
tensin-1, bradykinin and enkephalins which are also
implicated in sperm cell function [27,28] and might thus
be relevant to explain the tachykinin antagonist-resistant
component of the response to phosphoramidon. In fact,
the NEP inhibitor thiorphan increased sperm progres-
sive motility and the opioid receptor antagonist nalox-
one inhibited the effects observed after prolonged (4 h)
but not shorter (2 h) periods of incubation with thior-
phan [27]. It thus seems that both tachykinins and
opioids are involved in the responses observed after
neprilysin inhibition in human sperm without ruling out
the possible involvement of other peptide substrates.
Bioactive peptides i.e., opioids [27], bradykinin [28] or
tachykinins [[9], this study] are widely expressed in
sperm and many of the enzymes involved in their meta-
bolism are also present and are functionally active
[25,27,28]. Inhibition of these enzymes caused slowly
developing changes in sperm motility [[27,28], this
study]. Thus, these biopeptides, and particularly tachyki-
nins, could operate as signal molecules between sperma-
tozoa and their environment acting in an autocrine and/
or paracrine (effect on other cells, on the female genital
tract, and viceversa) fashion. In fact, NK1 NK2 and NK3
receptors are present in sperm and exogenously applied
tachykinins modulate progressive motility at nanomolar
concentrations [9]. Further studies will help to clarify
the precise role of neprilysins and neprylisin-sensitive
Figure 5 Tachykinin receptor-selective antagonists inhibit the effect of phosphoramidon on sperm motility.T h ee f f e c t so f
phosphoramidon (1 μM, 60 min incubation) on human sperm progressive motility (grade a+b sperm) were analyzed in the presence of
SR140333 (NK1 antagonist, 10 nM), SR48968 (NK2 antagonist, 10 nM), SR142801 (NK3 antagonist, 10 nM), a combination of the three antagonists,
or the antagonist solvent. Motility analysis was performed manually following WHO guidelines. Bars are means with SEM of 6-8 different
experiments and represent percentage changes in motility in samples treated with phosphoramidon relative to the value observed at the same
time in phosphoramidon solvent-treated paired controls. *P < 0.05, significant difference vs. response to phosphoramidon.
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Page 8 of 10peptides in the regulation of sperm physiology and male
fertility.
Conclusions
The present study shows that tachykinins and the tachy-
kinin-degrading enzymes NEP and NEP2 are present in
human spermatozoa and participate in the regulation of
sperm motility. These data support a role for the tachy-
kinin system in the regulation of sperm function.
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